Response to Comment on 'Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells'

Evers et al. employed CRISPR/Cas9 technology to generate B cell populations missing the BCR as an additional (negative) control, to investigate the contribution of the BCR in anti-CD20–mediated complement-dependent cytotoxicity (CDC) that we proposed ([1][1]). We agree with the notion that loss of